Alistair Gray
Gründer bei Renaissance Co., Inc.
Vermögen: 6 624 $ am 31.07.2023
Ursprung des Netzwerks ersten Grades von Alistair Gray
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Miscellaneous Commercial Services | 36 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Alistair Gray
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| University of Cambridge | College/University | Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
| University College London | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| E-THERAPEUTICS PLC | Biotechnology | Chairman Chief Executive Officer Chief Operating Officer Corporate Officer/Principal | |
| ARATANA THERAPEUTICS INC | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| Imperial College London | College/University | Doctorate Degree Doctorate Degree | |
| PREMIER VETERINARY GROUP PLC | Agricultural Commodities/Milling | Chairman Comptroller/Controller/Auditor | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Lonza Biologics Plc
 Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer Chief Executive Officer | |
| The University of Chicago | College/University | Masters Business Admin Corporate Officer/Principal | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Proteros biostructures GmbH
 Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Medical/Nursing Services | Director of Finance/CFO Chief Executive Officer | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| ENZON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| University of Oxford | College/University | Doctorate Degree Doctorate Degree | |
| PHARNEXT SCA | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
Women's Forum, Inc.
 Women's Forum, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Leadership Foundations, Women's Forum, Inc. is a non-profit community for women leaders of diverse achievement. The company is based in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| DIMENSION THERAPEUTICS INC | Biotechnology | Chief Executive Officer | |
| ARDELYX, INC. | Pharmaceuticals: Major | Director/Board Member | |
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | Miscellaneous Commercial Services | Director/Board Member | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Chairman | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Director/Board Member | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| St Bartholomew's Hospital Medical College | College/University | Doctorate Degree | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Institute of Tumour Biology | Corporate Officer/Principal | ||
| Philipps University of Marburg | College/University | Doctorate Degree | |
| Biotie Therapies, Inc. | Corporate Officer/Principal | ||
The University of Liverpool
 The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | College/University | Chief Operating Officer | |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Biotechnology | Director/Board Member | |
Women in Bio, Inc.
 Women in Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Women in Bio, Inc. is an organization that supports women in the life sciences industry. The non-profit company is based in Bethesda, MD and has subsidiaries in the United States. The organization has 13 chapters in the United States and is funded by sponsors and partners who are dedicated to supporting diversity and inclusion for women of all ages. Founded in 2002, it offers professional educational programs, peer-to-peer learning, mentoring, and networking opportunities for women at all career levels. Women in Bio was founded by Faith L. Charles and Cynthia Wong Hu. | Miscellaneous Commercial Services | Director/Board Member | |
Thrombolytic Science International LLC
 Thrombolytic Science International LLC Pharmaceuticals: MajorHealth Technology Thrombolytic Science International LLC operates as a vascular medicine and biotech company. The company was founded by Alexis Wallace and Victor Gurewich and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Oncimmune Ltd.
 Oncimmune Ltd. BiotechnologyHealth Technology Oncimmune Ltd. provides clinical testing services for cancer detection. The firm develops early cancer detection tests for lung, breast, colorectal, prostate, stomach, pancreatic and ovarian cancers. The company was founded by John F. R. Robertson in 2003 and is headquartered in Nottingham, the United Kingdom. | Biotechnology | Director/Board Member | |
| The European Commission | General Government | Corporate Officer/Principal | |
| London School of Hygiene & Tropical Medicine | College/University | Corporate Officer/Principal | |
| COMPASS PATHWAYS PLC | Biotechnology | Director/Board Member | |
| SENSYNE HEALTH PLC | Miscellaneous Commercial Services | Chairman | |
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
| AVROBIO, INC. | Biotechnology | Director/Board Member | |
PhESi LLC
 PhESi LLC Pharmaceuticals: MajorHealth Technology PhESi LLC provides drug and clinical development services for life sciences companies. The private company is based in East Lyme. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 23 |
| Vereinigtes Königreich | 17 |
| Deutschland | 4 |
| Dänemark | 3 |
| Schweiz | 3 |
Sektoral
| Health Technology | 31 |
| Consumer Services | 10 |
| Commercial Services | 6 |
| Finance | 2 |
| Process Industries | 2 |
Operativ
| Director/Board Member | 227 |
| Corporate Officer/Principal | 85 |
| Chairman | 73 |
| Chief Executive Officer | 51 |
| Independent Dir/Board Member | 45 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Annalisa Jenkins | 51 |
| Andrew Richards | 44 |
| Iain Ross | 41 |
| Stephen Parker | 34 |
| James Ede-Golightly | 29 |
| Michael Davidson | 27 |
| Stuart J. M. Collinson | 25 |
| Craig Tooman | 22 |
| David Solomon | 22 |
| David Lemus | 22 |
| Simon Sturge | 20 |
| Eric Floyd | 18 |
| Lucio Iannone | 17 |
| Mark Rothera | 14 |
| Torsten Hoffmann | 9 |
- Börse
- Insiders
- Alistair Gray
- Unternehmensverbindungen